骨髓间充质干细胞成肌和成脂分化的调控

骨髓间充质干细胞(mesenchymal stem cells,MSCs)是来源于骨髓基质的一类具有高度自我更新能力和多向分化潜能的成体干细胞.因其具有容易获取、体外扩增方便迅速、移植排斥反应较弱等优点而成为临床应用的理想细胞模型.骨髓间充质干细胞向成肌和成脂的分化对动物机体内肌肉和脂肪的组成具有直接影响,因而与肉品质及人类健康息息相关.本文综述了骨髓间充质干细胞定向分化为骨骼肌细胞和脂肪细胞的过程及其调控机制,并重点分析了关键调控因子PRDM16(PR domain-containing16)和骨形态发生蛋白(bone morphogenetic proteins,BMPs)在骨髓间充质干细胞成肌和成脂分化中的作用.     

干细胞概述

干细胞是存在于胚胎和成体中的一类特殊细胞,它能长期地自我更新,在特定的条件下具有分化形成多种终末细胞的能力,不同来源的干细胞分化潜能各异。从早期胚胎内细胞团分离的胚胎干细胞能分化形成个体所有的细胞类型,并具有在体外无限增殖的能力,是最具有临床应用前景和研究价值的干细胞之一。在成体各种组织和器官中也存在成体干细胞,用于维持机体结构和功能的稳态。近期有关成体干细胞可塑性的研究和成体组织中多能干细胞存在的证据扩大了人们对成体干细胞分化潜能的认识。干细胞具有的多向分化潜能和自我更新能力使其成为未来再生医学的重要种子细胞,并成为研究人类早期胚层特化和器官形成、药物筛选以及基因治疗的最佳工具。     

脂肪来源间充质干细胞体外定向诱导分化血管细胞的研究进展

脂肪来源的间充质干细胞具有较强的体外增殖能力,因具有生物学特性稳定、来源充足、体外培养条件低等优势已引起各国学者的关注。脂肪间充质干细胞凭借其多向分化潜能,是人体干细胞库潜在的重要来源之一。目前,研究人员已成功地在体外将其诱导为内皮细胞,成骨细胞、成软骨细胞、脂肪前体细胞、平滑肌细胞,心肌细胞、神经样细胞等。就脂肪来源的间充质干细胞体外定向诱导分化血管细胞的研究进展作一综述。     

干细胞对肝脏疾病的治疗现状及前景

一、国内外干细胞研究与应用现状干细胞生物学兴起为包括终末期肝病在内的多种难治性人类疾病治疗带来新的希望。干细胞具有高度的自我更新及多向分化潜能。自我更新特性使得干细胞可以成为一个源源不竭的细胞库,克服了肝细胞增殖能力有限的问题;多向分化潜能赋予干细胞一定的可塑性,分化为具有功能的肝细胞。在体外,将干细胞诱导分化为肝细胞,可以解决生物人工肝种子细胞来源困难的问题。在体内,将干细胞经肝动静脉回输入肝脏,从一定程度上提高终末     

胚胎干细胞模型的研究进展

胚胎干细胞是一种具有自我更新和多向分化潜能的细胞群,它的体外扩增、定向诱导分化在未来个体发育、基因和细胞治疗以及组织工程等方面的研究中具有不可估量的应用价值。简要回顾胚胎干细胞的研究进展和存在问题．对其未来的发展进行展望。     

脐血干细胞向不同体细胞分化的研究进展

脐血干细胞是一种具有多分化潜能的原始细胞,具备自我更新和增殖的能力,并能在特定因素的影响或诱导下,向多种细胞或组织分化。脐血来源的间充质干细胞不但可以分化为骨、脂肪和软骨,还可以转变成带有神经、肝脏及骨骼肌特异标记的细胞,并且具有应用到组织损伤修复、基因治疗载体和造血干细胞共移植等方面的潜力。旨在对于脐血干细胞在一定条件下分化为多种细胞研究进展进行综述。     

脐带血造血干细胞治疗糖尿病的研究进展

脐带血造血干细胞具有极强的自我更新和多向分化潜能,为治疗糖尿病开辟了新的途径,造血干细胞在生成胰岛素分泌细胞前需要经过诱导分化、细胞选择和细胞成熟三个阶段。目前,脐带血造血干细胞在治疗糖尿病中已取得一定进展,将造血干细胞定向分化为胰岛β细胞成为了治疗的关键。本文通过对脐带血的特征、造血干细胞的制备和移植、糖尿病的治疗以及脐带血造血干细胞移植的利与弊等方面进行的归纳总结,分析脐带血造血干细胞在治疗糖尿病方面的进展和应用前景。     

诱导小鼠胚胎干细胞在体外分化为骨骼肌细胞的实验研究

小鼠胚胎干细胞是从胚泡未分化的内部细胞团中得到的干细胞,它在体外培养的环境中具有无限增殖、自我更新以及多向分化的特性。将小鼠胚胎干细胞在体外诱导分化为肌肉细胞,并且利用这些分化得来的肌肉细胞治疗肌肉退行性疾病,是干细胞研究领域的热点。该实验的目的在于筛选小鼠胚胎干细胞向骨骼肌细胞定向分化的实验条件,有效地将体外单层贴壁培养的小鼠胚胎干细胞诱导分化成骨骼肌细胞。最终发现,10-8mol/L维甲酸(retinoid acid,RA)+0.5%二甲基亚砜(dimethyl sulfoxide,DMSO)组诱导小鼠胚胎干细胞在体外分化成骨骼肌前体细胞的效率最高,分化得到的骨骼肌前体细胞经进一步纯化,能分化为多核的肌管。该实验为治疗肌肉退行性疾病提供了细胞来源,也为研究小鼠胚胎干细胞分化为骨骼肌细胞的机制提供了有利的条件。     

脂肪细胞的发育分化

脂肪组织是人体重要的能量贮存器官,同时还是一个重要的内分泌器官。适量的脂肪组织为人体所必需,但过多或过少的脂肪组织都会引起代谢综合征。脂肪细胞起源于血管基质中多潜能干细胞,这类干细胞具有自我更新和多向分化的潜能,在合适的条件下不仅可以分化为脂肪细胞,还可分化为肌肉细胞、软骨细胞和成骨细胞等中胚层来源的细胞。从多潜能干细胞到脂肪细胞的发育阶段可被分为三个阶段：（1）多潜能干细胞;（2）前脂肪细胞;（3）脂肪细胞。目前本领域的研究集中在干细胞定向为前脂肪细胞的机理以及这些定向为前脂肪细胞的干细胞的来源。该文将对从多潜能干细胞发育分化为成熟脂肪细胞的过程进行详细的阐述。     

缺氧对于间充质干细胞分化的影响

间充质干细胞(mesenchymal stem cell,MSC),是来源于中胚层的具有自我更新能力和多向分化潜能干细胞,在体内外可以分化成骨、软骨、脂肪、肌腱和肌细胞等.由于其强大的分化潜能,MSC在组织工程与再生医学方面具有广泛的应用前景.MSC存在于高度受调控的被称为"壁龛"的微环境中.干细胞壁龛处于一个缺氧的环境中,氧分压可以低至7.2 mmHg.同时MSC是肿瘤微环境的重要的细胞组成成分,肿瘤微环境也是存在于一个缺氧的环境中.了解MSC在缺氧状态下的分化能力,对于组织工程、再生医学和肿瘤的发生发展研究具有重要的意义.缺氧相关的信号转导参与MSC定向分化能力的过程.目前MSC在缺氧状态下的成脂和成骨分化的研究存在着差异,这些研究结果的差异可能是由于MSC的异质性以及实验操作不同所引起.     

Adipose‐derived mesenchymal stem cells and regenerative medicine

Adipose tissue‐derived mesenchymal stem cells (ADSCs) are multipotent and can differentiate into various cell types, including osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β‐cells, and hepatocytes. Compared with the extraction of other stem cells such as bone marrow‐derived mesenchymal stem cells (BMSCs), that of ADSCs requires minimally invasive techniques. In the field of regenerative medicine, the use of autologous cells is preferable to embryonic stem cells or induced pluripotent stem cells. Therefore, ADSCs are a useful resource for drug screening and regenerative medicine. Here we present the methods and mechanisms underlying the induction of multilineage cells from ADSCs.     

脂肪干细胞的共培养及其分化应用概述

干细胞在体外特定培养条件下可以被诱导分化成具有不同体细胞表型的细胞。除了通过不同培养条件进行体外诱导分化的方法外,用成熟体细胞与干细胞共培养同样可以诱导干细胞定向分化。以下首先简述了脂肪干细胞 (Adipose-derived stem cells,ADSCs) 的来源及其标志,然后重点就ADSCs的不同培养方法、诱导分化及最新的临床应用进行阐述,包括药物及化学诱导培养、体细胞与ADSCs二维、三维共培养等,最后提出ADSCs的问题所在并对此技术进行展望。     

Current applications of adipose-derived stem cells and their future perspectives

Adult stem cells have a great potential to treat various diseases. For these cell-based therapies, adipose-derived stem cells(ADSCs) are one of the most promising stem cell types, including embryonic stem cells(ESCs) and induced pluripotent stem cells(iPSCs). ESCs and iPSCs have taken center stage due to their pluripotency. However, ESCs and iPSCs have limitations in ethical issues and in identification of characteristics, respectively. Unlike ESCs and iPSCs, ADSCs do not have such limitations and are not only easily obtained but also uniquely expandable. ADSCs can differentiate into adipocytes, osteoblasts, chondrocytes, myocytes and neurons under specific differentiation conditions, and these kinds of differentiation potential of ADSCs could be applied in regenerative medicine e.g., skin reconstruction, bone and cartilage formation, etc. In this review, the current status of ADSC isolation, differentiation and their therapeutic applications are discussed.     

脂肪干细胞在泌尿系统疾病中的研究进展

脂肪干细胞(adipose-derived stem cells,ADSCs)是一类从脂肪分离出来的具有自我更新及多向分化潜能的成体干细胞,ADSCs具有高度的可塑性,可分化成多种类型的细胞。与其他干细胞相比,ADSCs具有来源充足,取材方便,供体易接受等独特优势,已成为基础医学及临床治疗的研究热点。ADSCs诱导分化和移植可有效治疗多种组织损伤性疾病,改善或修复器官功能,近年来ADSCs作为细胞疗法及组织工程的新型种子细胞在泌尿系统疾病治疗中取得了重大进展。本文重点讨论ADSCs的生物学特性及其在泌尿系统疾病中的应用前景。     

Co-culture with neurotrophic factor secreting cells induced from adipose-derived stem cells: Promotes neurogenic differentiation

Adipose-derived stem cells (ADSCs) and bone marrow stem cells (BMSCs) can be equally proper in the treatment of neurodegenerative diseases. However, ADSCs have practical benefits. In this study, we attempted to induce the secretion of neurotrophic factors (NTF) in human ADSCs. We then evaluated the effects of co-culture with NTF secreting cells in neural differentiation of human ADSCs. Isolated human ADSCs were induced to neurotrophic factors secreting cells. To evaluate the in vitro effects of NTF-secreting ADSCs on neurogenic differentiation of ADSCs, we used neurogenic induction medium (control group), the combination of neurogenic medium and conditioned medium, or co-cultured NTF-secreting ADSCs which were encapsulated in alginate beads (co-culture) for 7 days. ELISA showed increased (by about 5 times) release of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in NTF-secreting ADSCs compared to human ADSCs. Real time RT-PCR analysis revealed that NTF-secreting ADSCs highly expressed NGF and BDNF. In addition, co-culture with NTF-secreting ADSCs could also promote neuronal differentiation relative to gliogenesis. Overall, NTF-secreting ADSCs secrete a range of growth factors whose levels in culture could promote neuronal differentiation and could support the survival and regeneration in a variety of neurodegenerative diseases.     

Characterization of in vitro cultured bone marrow and adipose tissue‐derived mesenchymal stem cells and their ability to express neurotrophic factors

MSCs (mesenchymal stem cells) have attracted attention as a promising tool for regenerative medicine and transplantation therapy. MSCs exert neuroprotective effects by secreting a number of factors in vitro and in vivo. Similar characteristics are found in ADSCs (adipose‐derived stem cells) and BMSCs (bone marrow stromal cells). Multipotent capability, easy accessibility and rapid proliferation of ADSCs have been established. Our main objective was to compare cell viability, growth rate, expression of neurotrophic factors and nestin genes in ADSCs and BMSCs. Cell doubling time and proliferation rate indicate that ADSCs has a higher proliferation rate than BMSCs. ADSCs and BMSCs express a similar pattern of CD71 and CD90 markers. Nestin immunostaining showed that ADSCs and BMSCs are immunopositive. The expression of neurotrophic factors genes in ADSCs proved similar to that of BMSCs genes. Thus adipose tissue stem cells with a high proliferation rate can express nestin and neurotrophic factor genes. Therefore ADSCs may be useful in future cell replacement therapies and help improve neurodegenerative diseases.     

Current evidence on potential of adipose derived stem cells to enhance bone regeneration and future projection

Injuries to the postnatal skeleton are naturally repaired through successive steps involving specific cell types in a process collectively termed “bone regeneration”. Although complex, bone regeneration occurs through a series of well-orchestrated stages wherein endogenous bone stem cells play a central role. In most situations, bone regeneration is successful; however, there are instances when it fails and creates non-healing injuries or fracture nonunion requiring surgical or therapeutic interventions. Transplantation of adult or mesenchymal stem cells (MSCs) defined by the International Society for Cell and Gene Therapy (ISCT) as CD105+CD90+CD73+CD45-CD34-CD14orCD11b-CD79αorCD19-HLA-DR- is being investigated as an attractive therapy for bone regeneration throughout the world. MSCs isolated from adipose tissue, adipose-derived stem cells (ADSCs), are gaining increasing attention since this is the most abundant source of adult stem cells and the isolation process for ADSCs is straightforward. Currently, there is not a single Food and Drug Administration (FDA) approved ADSCs product for bone regeneration. Although the safety of ADSCs is established from their usage in numerous clinical trials, the bone-forming potential of ADSCs and MSCs, in general, is highly controversial. Growing evidence suggests that the ISCT defined phenotype may not represent bona fide osteoprogenitors. Transplantation of both ADSCs and the CD105^- sub-population of ADSCs has been reported to induce bone regeneration. Most notably, cells expressing other markers such as CD146, AlphaV, CD200, PDPN, CD164, CXCR4, and PDGFRα have been shown to represent osteogenic sub-population within ADSCs. Amongst other strategies to improve the bone-forming ability of ADSCs, modulation of VEGF, TGF-β1 and BMP signaling pathways of ADSCs has shown promising results. The U.S. FDA reveals that 73% of Investigational New Drug applications for stem cell-based products rely on CD105 expression as the “positive” marker for adult stem cells. A concerted effort involving the scientific community, clinicians, industries, and regulatory bodies to redefine ADSCs using powerful selection markers and strategies to modulate signaling pathways of ADSCs will speed up the therapeutic use of ADSCs for bone regeneration.     

Current applications of adipose-derived stem cells and their future perspectives简

Adult stem cells have a great potential to treat various diseases. For these cell-based therapies, adipose-derived stem cells (ADSCs) are one of the most promising stem cell types, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). ESCs and iPSCs have taken center stage due to their pluripotency. However, ESCs and iPSCs have limitations in ethical issues and in identification of characteristics, respectively. Unlike ESCs and iPSCs, ADSCs do not have such limitations and are not only easily obtained but also uniquely expandable. ADSCs can differentiate into adipocytes, osteoblasts, chondrocytes, myocytes and neurons under specific differentiation conditions, and these kinds of differentiation potential of ADSCs could be applied in regenerative medicine e.g., skin reconstruction, bone and cartilage formation, etc. In this review, the current status of ADSC isolation, differentiation and their therapeutic applications are discussed.